[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585890":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":28,"locations":37,"responsibleParty":56,"collaborators":58,"id":62,"slug":20,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":20,"enrollmentInfo":72,"targetDuration":20,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":40,"whyStopped":20,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Duke University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PrEP","EXPERIMENTAL","All eligible participants will be given oral PrEP pills to reduce their risk for contracting HIV.",[13],"Drug: Pre-Exposure Prophylaxis (PrEP)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Pre-Exposure Prophylaxis (PrEP)","Oral Pre-Exposure Prophylaxis (PrEP) pills",[9],null,[22,26],{"name":23,"affiliation":24,"role":25},"Mehri McKellar, MD","Duke Health","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":24,"role":25},"Jacqueline Hodges, MD, MPH",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":20,"email":33},"Amelia R Ashkin-Baker, BA","CONTACT","(919)448-8680","amelia.ashkin-baker@duke.edu",{"name":35,"role":31,"phone":20,"phoneExt":20,"email":36},"Madelene Travis, BA","madelene.travis@duke.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Duke Department of Population Health Sciences","RECRUITING","Durham","North Carolina","27701","United States",{"type":46,"coordinates":47},"Point",[48,49],-78.89862,35.99403,{"lat":49,"lon":48},[52,54],{"name":27,"role":31,"phone":20,"phoneExt":20,"email":53},"jacqueline.hodges@duke.edu",{"name":55,"role":25,"phone":20,"phoneExt":20,"email":20},"Jaqueline Hodges, MD, MPH",{"type":57,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[59],{"name":60,"class":61},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100585890",false,"NCT06908252","MAPS PrEP Van Study","Integrating PrEP Into Mobile Addiction Treatment and Primary Care Services","MAPS PrEP","Inclusion Criteria:\n\n* 18 years or older, active drug injection user and\u002For sexually active, referred from the Syringe Service Program\n\nExclusion Criteria:\n\n* positive HIV status",true,"ALL","18 Years",{"count":73,"type":74},20,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","For this study the investigators aim to see if giving participants an oral HIV prevention medication on a medical van, is a good option of care for individuals who inject drugs and\u002For are sexually active and therefore at a higher risk of contracting HIV.",[80],"HIV Infection",[82,83,9,84,85],"People who inject drugs","Mobile Medical Unit","Syringe Service Program","HIV prevention","2026-01-16",{"date":88,"type":89},"2026-01-20","ACTUAL",{"date":91,"type":89},"2025-09-17",{"date":93,"type":74},"2026-07-31",{"name":5,"class":6},1]